Printer Friendly

THE LIPOSOME COMPANY ANNOUNCES RESEARCH MANAGEMENT REALIGNMENT

 PRINCETON, N.J., Sept. 30 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO, LIPOZ), announced today that David G. Shand, M.D., Ph.D., has resigned from his positions as executive vice president, chief scientific officer, and a director. He will continue to play an active role at the company as a clinical and regulatory consultant advising the company on clinical trials and FDA related matters.
 Charles A. Baker, chairman and chief executive officer of The Liposome Company, said, "Dr. Shand has made important contributions to the company during his tenure with us. He has led the recruitment of very valuable people and has made particularly strong contributions in the regulatory area. We are very pleased that Dr. Shand will be continuing to assist us in getting our products through clinical trials and to the market as rapidly as possible."
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases.
 The company has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; Maitec(TM) (formerly TLC G-65) is in Phase II trials in the U.S. and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 has completed Phase II trials for treatment for metastatic breast cancer; and TLC C-53 has completed Phase I trials in preparation for a Phase II study in Acute Respiratory Distress Syndrome.
 -0- 9/30/93
 /CONTACT: Brooks Boveroux, vice president-finance and CFO of The Liposome Company, 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER

TW-GK -- NY094 -- 7459 09/30/93 16:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1993
Words:303
Previous Article:CANDIE'S, INC., REPORTS SECOND QUARTER LOSS OF $1,865,887
Next Article:MAXSERV CONTINUES STRONG FINANCIAL PERFORMANCE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters